Dra. Ana Lluch Hernández

Investigador Principal
Grupo de Investigación en Biología en Cáncer de mama

Presentación


La Dra. Ana Lluch es Catedrática Emérita del área de Medicina de la Universitat de València y Coordinadora del Grupo de Investigación de Biología en Cáncer de Mama-INCLIVA.

Ha dirigido más de 40 tesis, presentado gran número de trabajos en los principales congresos nacionales y extranjeros, publicado más de 300 artículos en revistas nacionales e internacionales, colaborado en publicaciones de libros de la especialidad y por supuesto, participado activamente en conferencias tanto a nivel nacional como internacional.

Se le han concedido diversas becas de investigación, entre las que cabe destacar las 9 que reicibió como Investigador Principal en Proyectos del Fondo de Investigación Sanitaria del Instituto de Salud Carlos III.

Investigador
Principal
Dra. Ana Lluch Hernández

ana.lluch@uv.es

Publicaciones
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. Esmo Open. 2021 Jan 18;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. PMID: 33477007

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Feb 18. doi: 10.1021/acssensors.0c02222. PMID: 33599490

Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578

Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer. Guardia C, Bianchini G, Arpi-LLucia O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero J, Soria-Jimenez L, Sabbaghi M, Pena R, Madoz-Gurpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Clinical Cancer Research. 2021 Aug 12. doi: 10.1158/1078-0432.CCR-20-2915. PMID:34385295

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, Hauser J, Lindemann JPO, Maudsley R, McEwen R, Moschetta M, Nikolaou M, Schiavon G, Razavi P, Banerji U, Baselga J, Hyman DM, Chandarlapaty S. NPJ Breast Cancer. 2021 Apr 16;7(1):44. doi: 10.1038/s41523-021-00251-7. PMID: 33863913

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. Nunez-Torres R, Martin M, Garcia-Saenz J, Rodrigo-Faus M, Del Monte-Millan M, Tejera-Perez H, Pita G, de la Torre-Montero J, Pinilla K, Herraez B, Peiró Chová L, Bermejo De Las Heras B, Lluch Hernández A, Gonzalez-Neira A. JAMA Dermatology. 2020 Sep 1;156(9):987-991. doi: 10.1001/jamadermatol.2020.1867. PMID: 32756886

Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer. Zazo S, Gonzalez-Alonso P, Martin-Aparicio E, Chamizo C, Luque M, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles Asensio P, Lluch Hernández A, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Rojo F. Molecular Cancer Therapeutics. 2020 Aug;19(8):1696-1707. doi: 10.1158/1535-7163.MCT-19-1172. PMID: 32404410

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. Garrido Cano I, Constancio V, Adam Artigues A, Lameirinhas A, Simon Alonso S, Ortega Morillo B, Martinez Martinez M, Hernando Meliá C, Bermejo De Las Heras B, Lluch Hernández A, Lopes P, Henrique R, Jeronimo C, Cejalvo Andujar J, Eroles Asensio P. International Journal of Molecular Sciences. 2020 Oct 8;21(19):7427. doi: 10.3390/ijms21197427. PMID: 33050096

Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study. Trivino J, Ceba A, Rubio-Solsona E, Serra D, Sanchez-Guiu I, Ribas G, Rosa R, Cabo M, Bernad L, Pita G, Gonzalez-Neira A, Legarda G, Diaz J, García Vigara A, Martinez Aspas A, Escrig M, Bermejo De Las Heras B, Eroles Asensio P, Ibanez J, Salas D, Julve Parreño A, Cano Sanchez A, Lluch Hernández A, Minambres R, Benitez J. BMC Cancer.2020 Nov 10;20(1):1079. doi: 10.1186/s12885-020-07584-9. PMID: 33167914

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. Garcia-Recio S, Thennavan A, East M, Parker J, Cejalvo J, Garay J, Hollern D, He X, Mott K, Galvan P, Fan C, Selitsky S, Coffey A, Marron D, Braso-Maristany F, BURGUES GASION O, Albanell J, Rojo F, Lluch Hernández A, Martinez de Duenas E, Rosen J, Johnson G, Carey L, Prat A, Perou C. Journal of Clinical Investigation. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. PMID: 32573490

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. Oltra Sanchis S, Cejalvo Andujar J, Tormo Martin E, Albanell M, Ferrer A, Nacher M, Bermejo De Las Heras B, Hernando Meliá C, Chirivella González I, Alonso Yuste E, Burgues Gasion O, Peña Chilet M, Eroles Asensio P, Lluch Hernández A, Ribas Despuig G, Martinez Martinez M. Cancers. 2020 Feb 10;12(2):412. doi: 10.3390/cancers12020412. PMID: 32050699

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma. Pattanayak C, Garrido Cano I, Adam Artigues A, Tormo Martin E, Pineda Merlo B, Cabello Navarro P, Alonso Yuste E, Bermejo De Las Heras B, Hernando Meliá C, Martinez Martinez M, Rovira A, Albanell J, Rojo F, Burgues Gasion O, Cejalvo Andujar J, Lluch Hernández A, Eroles Asensio P. Frontiers in Oncology. 2020 Sep 10;10:1661. doi: 10.3389/fonc.2020.01661. PMID: 33014831

Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). Ciruelos E, Montano A, Rodriguez C, Gonzalez-Flores E, Lluch Hernández A, Garrigos L, Quiroga V, Anton A, Malon D, Chacon J, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri M, Munoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. European Journal of Cancer Care. 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. PMID: 32578279

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Lluch Hernández A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz J, Torres R, de la Haba J, Garcia-Martinez E, Gomez H, Llombart A, Salvador Bofill J, Baena-Canada J, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernandez I, Rodriguez-Lescure A, Cardenas J, Vinholes J, Martinez de Duenas E, Godes M, Segui M, Anton A, Lopez-Alvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero M, Bezares S, Carrasco E, Martin M, Corona J, Jara C, Cardemil B, Toro R, Pimentel C, Hernando B, Vicente E, Zagame L, Gil M, Garcia Estevez L, Rodriguez C, de la Cruz M, Tello J, Campos S, Lomas M, Capdevile D, Campos M, Margeli M, Andres R, Tusquets I, Ballesteros A, Guerrero A, Arguello M, Rodriguez J, Munoz M, Florian J, Azevedo S, Mondragon R, Peralta J, Palomo A, Barajas L, Arcusa A, Carranza H, Garcia C, Umbria C, Ales J, Lopez Vega J, Romeo M, Valero J, Alonso J, Mathias C, Gutierrez F, Adrover E, Nunez P, Mendiola C, Cassinello J, de la Huerta A, Geicam Spanish Breast Canc Grp, CIBOMA Iberoamer Coalition Res Bre, LACOG. Journal of Clinical Oncology. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. PMID: 31804894

Reply to Y. Usui et al. Lluch Hernández A, Barrios C, Torrecillas L, Martin M. Journal of Clinical Oncology. 2020 Jun 20;38(18):2113-2114. doi: 10.1200/JCO.20.00390. PMID: 32352858

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.. Gonzalez-Alonso P, Zazo S, Martin-Aparicio E, Luque M, Chamizo C, Sanz-Alvarez M, Minguez P, Gomez-Lopez G, Cristobal I, Carames C, Garcia-Foncillas J, Eroles Asensio P, Lluch Hernández A, Arpi O, Rovira A, Albanell J, Piersma S, Jimenez C, Madoz-Gurpide J, Rojo F. Cancers. 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108. PMID: 32365528

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Fernandez-Nogueira P, Mancino M, Fuster G, Lopez-Plana A, Jauregui P, Almendro V, Enreig E, Menendez S, Rojo F, Noguera-Castells A, Bill A, Gaither L, Serrano L, Recalde-Percaz L, Moragas N, Alonso R, Ametller E, Rovira A, Lluch Hernández A, Albanell J, Gascon P, Bragado P. Clinical Cancer Research. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. PMID: 31699826

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Pascual T, Martin M, Fernández-Martínez A, Paré L, Alba E, Rodríguez-Lescure Á, Perrone G, Cortés J, Morales S, Lluch A, Urruticoechea A, González-Farré B, Galván P, Jares P, Rodriguez A, Chic N, Righi D, Cejalvo JM, Tonini G, Adamo B, Vidal M, Villagrasa P, Muñoz M, Prat A. Frontiers in Oncology. 2019 Apr 26;9:303. doi: 10.3389/fonc.2019.00303. PMID: 31106144

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P. Clinical Epigenetics. 2019 Feb 20;11(1):33. doi: 10.1186/s13148-019-0626-0. PMID: 30786922

Acceleration in the DNA methylation age in breast cancer tumours from very young women. Oltra SS, Peña-Chilet M, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM, Ribas G. Scientific Reports. 2019 Oct 18;9(1):14991. doi: 10.1038/s41598-019-51457-6. PMID: 31628391

Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. Liu ZB, Ezzedine NE, Eterovic AK, Ensor JE, Huang HJ, Albanell J, Choi DS, Lluch A, Liu Y, Rojo F, Wong H, Martínez-Dueñas E, Guerrero-Zotano Á, Shao ZM, Darcourt JG, Mills GB, Dave B, Chang JC. Breast Cancer Research and Treatment. 2019 Nov;178(2):251-261. doi: 10.1007/s10549-019-05374-x. PMID: 31388936

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. Rodriguez BJ, Córdoba GD, Aranda AG, Álvarez M, Vicioso L, Pérez CL, Hernando C, Bermejo B, Parreño AJ, Lluch A, Ryder MB, Jones FS, Fredebohm J, Holtrup F, Queipo-Ortuño MI, Alba E. Journal of Clinical Medicine. 2019 Aug 7;8(8):1183. doi: 10.3390/jcm8081183. PMID: 31394872

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. Lluch A, González-Angulo AM, Casadevall D, Eterovic AK, Martínez de Dueñas E, Zheng X, Guerrero-Zotano Á, Liu S, Pérez R, Chen K, Chacón JI, Mills GB, Antolín S, Blancas I, López-Serra P, Carrasco E, Caballero R, Prat A, Rojo F, Gonzalez-Perez A, Meric-Bernstam F, Albanell J. European journal of cáncer. 2019 Oct;120:54-64. doi: 10.1016/j.ejca.2019.07.003. PMID: 31491604

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors (vol 24, pg 2517, 2018). Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL. Clinical Cancer Research. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. PMID: 30770490

High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer. Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M. Cancer Immunology Research. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. PMID: 31189644

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. Colomer R, Saura C, Sánchez-Rovira P, Pascual T, Rubio IT, Burgués O, Marcos L, Rodríguez CA, Martín M, Lluch A. Oncologist. 2019 May;24(5):603-611. doi: 10.1634/theoncologist.2018-0228. PMID: 30710068

NK Cell Infiltrates and HLA Class I Expression in Primary HER2(+) Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, López-Botet M, Albanell J. Clinical Cancer Research. 2019 Mar 1;25(5):1535-1545. doi: 10.1158/1078-0432.CCR-18-2365. PMID: 30523021

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. Lope V, Martín M, Castelló A, Ruiz A, Casas AM, Baena-Cañada JM, Antolín S, Ramos-Vázquez M, García-Sáenz JÁ, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Sánchez-Rovira P, Antón A, Chacón JI, Arcusa A, Jimeno MA, Bezares S, Vioque J, Carrasco E, Pérez-Gómez B, Pollán M. Scientific Reports. 2019 Mar 7;9(1):3904. doi: 10.1038/s41598-019-39346-4. PMID: 30846706

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. Scientific Reports. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y. PMID: 30926829

Proyectos
Referencia: CB16/12/00481
Título: CIBER Cáncer de mama
Entidad Financiadora: Instituto de Salud Carlos III
Investigador principal: Ana Lluch Hernández, Emilio Alba Conejo
Duración: 2017 – 2020
Presupuesto: